NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
21/02/2024
Voltar para busca
Dado oficial do USPTO
SERACARE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
70
Atualização mais recente
21/02/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 42
Data de depósito
22/09/2009
Data de registro
17/12/2013
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
21/02/2024
Última transação
21/02/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
800
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
26/09/2001
Primeiro uso no comércio
26/09/2001
Código do desenho
4
Tipo de titular
03
Localização do titular
MILFORD, MA
Examinador
JUN,WON KYUNG WENDY
Unidade examinadora
L30
Localização atual
GENERIC WEB UPDATE
Titulares e representantes
Titulares
LGC CLINICAL DIAGNOSTICS, INC.
SERACARE LIFE SCIENCES, INC.
Representantes
Mainak H. Mehta Procopio, Cory, Hargreaves & Savitch LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Diagnostic chemicalsreagents or preparations for scientificresearch or manufacturing use in chemicalpharmaceutical and biotechnology industries; Diagnostic reagents for clinicalmedical laboratory or manufacturing use in chemicalpharmaceutical and biotechnology industries; Diagnostic reagents for in vitro use in biochemistryclinical chemistrymicrobiology; Reagents and toolsanimal serumsbovine serum albuminhuman blood productsplasmaserumcellshuman serum albuminchromogenic substratesall for research purposes or manufacturing use in chemicalpharmaceutical and biotechnology industries; Chemical reagents other than for medical or veterinary purposes; Chemical preparations for scientific purposes; Chemical ingredients for use as exipients or diluents in the manufacture of pharmaceuticals; Chemical reagents for reference controlgenetic testing controls and controls for the testing of human seruminfectious disease antibodies and antigensviral nucleic acidsall for industrial use and not for medical purposes; Chemical solutions in the nature of quality control standard solutions for testing human seruminfectious disease antibodies and antigenshuman geneticsviral nucleic acidsall for industrial use and not for medical purposes; Chemical control serum for scientific or research use in the nature of quality controls for infectious disease and genetic testing; Biochemical control serum for scientific or research use in the nature of quality controls for infectious disease and genetic testing; Biochemical standard serum for scientific or research use; Quality control standard solutions and quality control materials for testing and calibrating medical apparatus and reagents for scientific and research purposes and for clinical or medical laboratory use; Standard serumcontrol serumbiochemical standard serumbiochemical control serum for scientific and research purposes and for clinical or medical laboratory use
Classe 5
Diagnostic reagents for medical and veterinary use; Clinical medical reagents; Diagnostic chemicalsreagents or preparations for medical and veterinary use; Chemical reagents for medical and veterinary use; Chemical reagents for pharmaceutical purposes and use in the pharmaceutical industrychemical reagents for use as diluents and excipients; Testing reagents for medical or clinical use; Genetic testing controls for the testing of human seruminfectious disease antibodies and antigensviral nucleic acidsmedical diagnostic reagents and assays; Chemical reference materialsquality controls and panels in the nature of human compounds for medical or veterinary use; Chemical reference specimensserologicalviralgenetic and nucleic acid reference specimens in the nature of human seruminfectious disease antibodies and antigens for medical or veterinary use
Classe 42
Custom design and development of chemical reagents and biochemical assays; Providing reagent sample testing for others in the fields ofscience and research related thereto; Research support services in the nature of assay development and validationproduct developmentreport generationall in the fields of virologyimmunologicalbiological and biochemical research
Publicações
Histórico de despachos e eventos da marca no USPTO.
70 publicações encontradas
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
21/02/2024
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
21/02/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
21/02/2024
E89R
TEAS SECTION 8 & 9 RECEIVED
26/08/2023
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
17/12/2022
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
05/10/2022
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
10/08/2020
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
10/08/2020
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
10/08/2020
E815
TEAS SECTION 8 & 15 RECEIVED
12/06/2020
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
17/12/2018
R.PR
REGISTERED-PRINCIPAL REGISTER
17/12/2013
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
13/11/2013
REGV
LAW OFFICE REGISTRATION REVIEW COMPLETED
12/11/2013
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
11/11/2013
SUPC
STATEMENT OF USE PROCESSING COMPLETE
06/11/2013
IUAF
USE AMENDMENT FILED
24/10/2013
EISU
TEAS STATEMENT OF USE RECEIVED
24/10/2013
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
02/05/2013
EX3G
SOU EXTENSION 3 GRANTED
01/05/2013
EXT3
SOU EXTENSION 3 FILED
25/04/2013
EEXT
SOU TEAS EXTENSION RECEIVED
25/04/2013
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
31/10/2012
EX2G
SOU EXTENSION 2 GRANTED
30/10/2012
EXT2
SOU EXTENSION 2 FILED
25/10/2012
EEXT
SOU TEAS EXTENSION RECEIVED
25/10/2012
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
17/05/2012
EX1G
SOU EXTENSION 1 GRANTED
16/05/2012
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
16/05/2012
EXT1
SOU EXTENSION 1 FILED
25/04/2012
EEXT
SOU TEAS EXTENSION RECEIVED
25/04/2012
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
25/10/2011
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
30/08/2011
PUBO
PUBLISHED FOR OPPOSITION
30/08/2011
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
26/07/2011
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
20/07/2011
XAEC
EXAMINER'S AMENDMENT ENTERED
19/07/2011
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
18/07/2011
GNEA
EXAMINERS AMENDMENT E-MAILED
18/07/2011
CNEA
EXAMINERS AMENDMENT -WRITTEN
18/07/2011
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
23/03/2011
GNRT
NON-FINAL ACTION E-MAILED
23/03/2011
CNRT
NON-FINAL ACTION WRITTEN
23/03/2011
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
15/03/2011
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
28/02/2011
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
17/02/2011
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
17/02/2011
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/02/2011
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/02/2011
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/02/2011
CEPE
COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION ENTERED
01/02/2011
GEAN
NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
31/01/2011
GEAP
EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
31/01/2011
CPEA
EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
31/01/2011
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
13/10/2010
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
29/07/2010
GNFR
FINAL REFUSAL E-MAILED
29/07/2010
CNFR
FINAL REFUSAL WRITTEN
29/07/2010
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/07/2010
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/07/2010
ALIE
ASSIGNED TO LIE
09/07/2010
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
21/06/2010
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
19/12/2009
GNRT
NON-FINAL ACTION E-MAILED
19/12/2009
CNRT
NON-FINAL ACTION WRITTEN
19/12/2009
DOCK
ASSIGNED TO EXAMINER
18/12/2009
MPMK
NOTICE OF PSEUDO MARK MAILED
26/09/2009
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
25/09/2009
NWAP
NEW APPLICATION ENTERED
25/09/2009
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace SERACARE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.